ArticleBrain and behavior2026
Prognostic Value of the Endothelial Activation and Stress Index (EASIX) in Critically Ill Patients With Ischemic Stroke: A MIMIC-IV Database Analysis.
Article in Brain and behavior, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundSystemic endothelial dysfunction is a critical driver of poor outcomes in ischemic stroke. We evaluated the prognostic value of the endothelial activation and stress index (EASIX) in critically ill stroke patients.
methodsWe analyzed 3063 patients with ischemic stroke from the MIMIC-IV database. The natural log-transformed EASIX (lnEASIX) was calculated from admission LDH, creatinine, and platelets. The primary outcome was designated as 28-day mortality, with secondary outcomes including in-hospital, 90-day, and 180-day mortality. Multivariable logistic and Cox proportional hazards regression, restricted cubic splines (RCS), and advanced clinical utility analyses (NRI, IDI, and decision curve analysis) were utilized.
resultsEvaluated as a continuous variable, a per-unit increase in lnEASIX was independently associated with an elevated risk for the primary endpoint of 28-day mortality (OR 1.47, 95% CI 1.36-1.59, p < 0.001), as well as all secondary mortality endpoints. RCS analysis confirmed a strictly linear, monotonic dose-response relationship (p for nonlinearity > 0.05). While lnEASIX demonstrated moderate standalone discrimination (AUC 0.64-0.67, comparable to SOFA), integrating it with the baseline SOFA score yielded significant incremental predictive value (NRI 0.208, IDI 0.011; both p < 0.01) and superior net clinical benefit. Subgroup analysis revealed consistent prognostic utility across most strata, though the impact was markedly more pronounced in patients without pre-existing cancer (p for interaction < 0.05).
conclusionLnEASIX is a simple, robust, and continuous predictor of short- and long-term mortality in critically ill patients with ischemic stroke. Integrating this zero-cost biomarker with established intensive care scoring systems provides significant incremental value for early prognostic risk stratification.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.